Literature DB >> 16972724

Planning and analyzing adaptive group sequential survival trials.

Gernot Wassmer1.   

Abstract

The use of adaptive methods has experienced increasing interest in the current literature on group sequential designs. Group sequential analysis in survival trials usually apply the error spending function approach due to the unpredictable amount of information available in an interim analysis. An alternative way is to apply adaptive methods where additionally the maximum amount of information and other designing parameters can be changed based on the information available at the interim stage. In this paper, it is shown how the inverse normal method can be used within a survival design using the log-rank test for comparing two survival functions. This method allows for many kinds of design modifications. In case of no modifications, the inverse normal method coincides with the commonly used analysis strategy. It is straightforward to specify effect estimates. Confidence intervals for the hazard ratio that can be calculated at each stage of the trial and intervals that can only be computed by the end of the trial are proposed. The latter also enables the calculation of median unbiased estimates. Overall p-values can be defined analogously. Properties of the analyses techniques are investigated and compared with alternative approaches. It is shown that the proposed analysis technique might help to rescue an underpowered study and opens the way to other types of changes in design. The proposed technique is implemented in the software ADDPLAN Adaptive Design, Plans and Analyses (http://www.addplan.com).

Mesh:

Year:  2006        PMID: 16972724     DOI: 10.1002/bimj.200510190

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  16 in total

1.  Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.

Authors:  Geraldine Rauch; Bernhard Rauch; Svenja Schüler; Meinhard Kieser
Journal:  World J Cardiol       Date:  2015-01-26

2.  Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Authors:  Peter K Kimani; Susan Todd; Lindsay A Renfro; Ekkehard Glimm; Josephine N Khan; John A Kairalla; Nigel Stallard
Journal:  Stat Med       Date:  2020-05-03       Impact factor: 2.373

3.  Sequential tests for non-proportional hazards data.

Authors:  Matthias Brückner; Werner Brannath
Journal:  Lifetime Data Anal       Date:  2016-03-11       Impact factor: 1.588

4.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Madhukar H Trivedi; Adam Janik; Honglan Li; Yun Zhang; Xiang Li; Rosanne Lane; Pilar Lim; Anna R Duca; David Hough; Michael E Thase; John Zajecka; Andrew Winokur; Ilona Divacka; Andrea Fagiolini; Wieslaw J Cubala; István Bitter; Pierre Blier; Richard C Shelton; Patricio Molero; Husseini Manji; Wayne C Drevets; Jaskaran B Singh
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

5.  The Effectiveness of Leech Therapy in Chronic Low Back Pain.

Authors:  Christoph-Daniel Hohmann; Rainer Stange; Nico Steckhan; Sibylle Robens; Thomas Ostermann; Arion Paetow; Andreas Michalsen
Journal:  Dtsch Arztebl Int       Date:  2018-11-23       Impact factor: 5.594

6.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

7.  Methods of designing two-stage winner trials with survival outcomes.

Authors:  Fang Fang; Yong Lin; Weichung J Shih; Yulin Li; Jay Yang; Xiaosha Zhang
Journal:  Stat Med       Date:  2013-12-18       Impact factor: 2.373

8.  High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

Authors:  Jeremy Whelan; Marie-Cecile Le Deley; Uta Dirksen; Gwénaël Le Teuff; Bernadette Brennan; Nathalie Gaspar; Douglas S Hawkins; Susanne Amler; Sebastian Bauer; Stefan Bielack; Jean-Yves Blay; Stefan Burdach; Marie-Pierre Castex; Dagmar Dilloo; Angelika Eggert; Hans Gelderblom; Jean-Claude Gentet; Wolfgang Hartmann; Wolf-Achim Hassenpflug; Lars Hjorth; Marta Jimenez; Thomas Klingebiel; Udo Kontny; Jarmila Kruseova; Ruth Ladenstein; Valerie Laurence; Cyril Lervat; Perrine Marec-Berard; Sandrine Marreaud; Jean Michon; Bruce Morland; Michael Paulussen; Andreas Ranft; Peter Reichardt; Hendrik van den Berg; Keith Wheatley; Ian Judson; Ian Lewis; Alan Craft; Heribert Juergens; Odile Oberlin
Journal:  J Clin Oncol       Date:  2018-09-06       Impact factor: 44.544

9.  High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Authors:  Uta Dirksen; Bernadette Brennan; Marie-Cécile Le Deley; Nathalie Cozic; Henk van den Berg; Vivek Bhadri; Bénédicte Brichard; Line Claude; Alan Craft; Susanne Amler; Natalie Gaspar; Hans Gelderblom; Robert Goldsby; Richard Gorlick; Holcombe E Grier; Jean-Marc Guinbretiere; Peter Hauser; Lars Hjorth; Katherine Janeway; Heribert Juergens; Ian Judson; Mark Krailo; Jarmila Kruseova; Thomas Kuehne; Ruth Ladenstein; Cyril Lervat; Stephen L Lessnick; Ian Lewis; Claude Linassier; Perrine Marec-Berard; Neyssa Marina; Bruce Morland; Hélène Pacquement; Michael Paulussen; R Lor Randall; Andreas Ranft; Gwénaël Le Teuff; Keith Wheatley; Jeremy Whelan; Richard Womer; Odile Oberlin; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2019-09-25       Impact factor: 50.717

10.  A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.

Authors:  Zhiwei Jiang; Ling Wang; Chanjuan Li; Jielai Xia; Hongxia Jia
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.